Online inquiry

IVTScrip™ mRNA-Anti-IL6R, SA-237(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14529MR)

This product GTTS-WQ14529MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets IL6R gene. The antibody can be applied in Neuromyelitis optica (NMO) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000565.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3570
UniProt ID P08887
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL6R, SA-237(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ14529MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6180MR IVTScrip™ mRNA-Anti-CD40, CP-870893(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CP-870893
GTTS-WQ4358MR IVTScrip™ mRNA-Anti-B7, BMS-188667(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-188667
GTTS-WQ663MR IVTScrip™ mRNA-Anti-CD276, 8H9(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 8H9
GTTS-WQ641MR IVTScrip™ mRNA-Anti-AOC3, 8c10(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 8c10
GTTS-WQ11383MR IVTScrip™ mRNA-Anti-IGF, MEDI-573(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MEDI-573
GTTS-WQ3320MR IVTScrip™ mRNA-Anti-lukG&lukH, ASN-100(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ASN-100
GTTS-WQ7716MR IVTScrip™ mRNA-Anti-GLP1R, GLP-1Fc(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GLP-1Fc
GTTS-WQ13771MR IVTScrip™ mRNA-Anti-MSTN, REGN-1033(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA REGN-1033
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW